Kyprolis (carfilzomib) is licensed for use in combination with the standard treatment of Celgene's Revlimid (lenalidomide) and dexamethasone in patients who have received at least one prior therapy.

Onyx Pharmaceuticals, Inc. has announced that the US FDA’s Oncologic Drug Advisory Committee (ODAC) has given a positive vote towards Kyprolis, which is being developed by Onyx Pharma for use in ...